Triple-Negative Breast Cancer (TNBC) Withdrawn Phase 2 Trials for Bavituximab (DB05136)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02685306A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast CancerTreatment